189 related articles for article (PubMed ID: 21321983)
1. Phosphorylated Akt up-regulates angiotensin II type-1 receptor expression in castration resistant prostate cancer.
Kosaka T; Miyajima A; Shirotake S; Kikuchi E; Oya M
Prostate; 2011 Oct; 71(14):1510-7. PubMed ID: 21321983
[TBL] [Abstract][Full Text] [Related]
2. Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer.
Kosaka T; Miyajima A; Shirotake S; Kikuchi E; Hasegawa M; Mikami S; Oya M
Prostate; 2010 Feb; 70(2):162-9. PubMed ID: 19760626
[TBL] [Abstract][Full Text] [Related]
3. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II/angiotensin II type I receptor (AT1R) signaling promotes MCF-7 breast cancer cells survival via PI3-kinase/Akt pathway.
Zhao Y; Chen X; Cai L; Yang Y; Sui G; Fu S
J Cell Physiol; 2010 Oct; 225(1):168-73. PubMed ID: 20458733
[TBL] [Abstract][Full Text] [Related]
5. Regulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer.
Shirotake S; Miyajima A; Kosaka T; Tanaka N; Kikuchi E; Mikami S; Okada Y; Oya M
Am J Pathol; 2012 Mar; 180(3):1008-1016. PubMed ID: 22226738
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer.
Kosaka T; Miyajima A; Takayama E; Kikuchi E; Nakashima J; Ohigashi T; Asano T; Sakamoto M; Okita H; Murai M; Hayakawa M
Prostate; 2007 Jan; 67(1):41-9. PubMed ID: 17044086
[TBL] [Abstract][Full Text] [Related]
7. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
[TBL] [Abstract][Full Text] [Related]
8. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
Liu L; Dong X
PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of the Ang II/AT1 receptor may compensate for the loss of gastric antrum ICC via the PI3k/Akt signaling pathway in STZ-induced diabetic mice.
Zhang CM; Huang X; Lu HL; Meng XM; Liu DH; Kim YC; Xu WX
Mol Cell Endocrinol; 2016 Mar; 423():77-86. PubMed ID: 26773730
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II enhances the proliferation of Natural Killer/T-cell lymphoma cells via activating PI3K/Akt signaling pathway.
Zhang GH; Miao FA; Xu JG; Zhang Y
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32969473
[TBL] [Abstract][Full Text] [Related]
11. Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer.
Kosaka T; Miyajima A; Shirotake S; Suzuki E; Kikuchi E; Oya M
J Urol; 2011 Jun; 185(6):2376-81. PubMed ID: 21511293
[TBL] [Abstract][Full Text] [Related]
12. Ang II-AT1R increases cell migration through PI3K/AKT and NF-κB pathways in breast cancer.
Zhao Y; Wang H; Li X; Cao M; Lu H; Meng Q; Pang H; Li H; Nadolny C; Dong X; Cai L
J Cell Physiol; 2014 Nov; 229(11):1855-62. PubMed ID: 24692224
[TBL] [Abstract][Full Text] [Related]
13. Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: angiotensin II type 1 receptor-independent effects of EXP3179.
Watanabe T; Suzuki J; Yamawaki H; Sharma VK; Sheu SS; Berk BC
Circulation; 2005 Sep; 112(12):1798-805. PubMed ID: 16172287
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin type 1 receptor mediates thyroid hormone-induced cardiomyocyte hypertrophy through the Akt/GSK-3beta/mTOR signaling pathway.
Diniz GP; Carneiro-Ramos MS; Barreto-Chaves ML
Basic Res Cardiol; 2009 Nov; 104(6):653-67. PubMed ID: 19588183
[TBL] [Abstract][Full Text] [Related]
15. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
16. PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer.
Yasumizu Y; Hongo H; Kosaka T; Mikami S; Nishimoto K; Kikuchi E; Oya M
Oncotarget; 2018 Jun; 9(45):27698-27707. PubMed ID: 29963230
[TBL] [Abstract][Full Text] [Related]
17. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
Fang J; Ding M; Yang L; Liu LZ; Jiang BH
Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033
[TBL] [Abstract][Full Text] [Related]
18. Limited in vitro efficacy of CYP17A1 inhibition on human castration resistant prostate cancer.
Kosaka T; Miyajima A; Yasumizu Y; Miyazaki Y; Kikuchi E; Oya M
Steroids; 2014 Dec; 92():39-44. PubMed ID: 25150014
[TBL] [Abstract][Full Text] [Related]
19. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine.
Xie X; Tang B; Zhou J; Gao Q; Zhang P
Oncol Rep; 2013 Aug; 30(2):773-82. PubMed ID: 23743572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]